

If a conflict arises between a Clinical Payment and Coding Policy and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern. "Plan documents" include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. Blue Cross and Blue Shield of Oklahoma may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSOK has full and final discretionary authority for their interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing Editor, American Medical Association, Current Procedural Terminology, CPT® Assistant, Healthcare Common Procedure Coding System, ICD-10 CM and PCS, National Drug Codes, Diagnosis Related Group guidelines, Centers for Medicare and Medicaid Services National Correct Coding Initiative Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services/procedures billed. Claim submissions are subject to claim review including but not limited to, any terms of benefit coverage, provider contract language, medical policies, clinical payment and coding policies as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

Celiac Disease Testing

Policy Number: CPCPLAB017

Version 1.0

Approval Date: 09/26/2025

Plan Effective Date: 01/03/2026

Description

The Plan has implemented certain lab management reimbursement criteria. Not all requirements apply to each product. Providers are urged to review Plan documents for eligible coverage for services rendered.

Reimbursement Information:

1. For individuals who have been diagnosed with celiac disease and who are IgA sufficient, serologic testing with IgA anti-tissue transglutaminase (TTG) **may be reimbursable** at the following intervals:
 - At the first follow-up visit 3 to 6 months after diagnosis;
 - Every 6 months until normalization of anti-TTG levels has occurred;
 - Every 12 to 24 months thereafter.
2. For individuals who have been diagnosed with celiac disease and who are IgA deficient, testing for IgG endomysial antibodies, IgG deamidated gliadin peptide, or IgG TTG **may be reimbursable** at the following intervals:
 - At the first follow-up visit 3 to 6 months after diagnosis;
 - Every 6 months until normalization of IgG levels has occurred;
 - Every 12 to 24 months thereafter.
3. For individuals with signs and symptoms of celiac disease (**Note 1**), serologic testing with the IgA anti-tissue transglutaminase (TTG) **and** the total IgA test for the diagnosis of celiac disease **may be reimbursable**.
4. For individuals at risk for celiac disease (**Note 1**), when IgA anti-TTG is negative or weakly positive, testing for IgA endomysial antibodies **may be reimbursable**.
5. For individuals with clinical suspicion of celiac disease (**Note 1**) with an IgA deficiency, testing for IgG endomysial antibodies, IgG deamidated gliadin peptide, or IgG TTG **may be reimbursable**.
6. Testing for IgA and IgG antibodies to deamidated gliadin peptides **may be reimbursable** in any of the following situations:
 - For individuals under 2 years of age with a clinical suspicion of celiac disease (**Note 1**);
 - For individuals over 2 years of age as a substitute for anti-TTG testing.
7. For confirmation of celiac disease in individuals at high risk for celiac disease, regardless of the result of celiac disease serology testing, pathological examination obtained from a biopsy of the small intestine **may be reimbursable**.
8. Rapid antigen point-of-care testing for anti-TTG **is not reimbursable**.

9. Panel testing, multiplex testing, or multi-analyte testing (for more than two analytes) for the diagnosis or the evaluation of celiac disease **is not reimbursable**.
10. For asymptomatic individuals not at an increased risk for developing celiac disease (**Note 1**), testing for celiac disease **is not reimbursable**.
11. Testing for anti-reticulin antibodies **is not reimbursable** for the diagnosis of celiac disease.
12. Testing of stool or saliva samples for the evaluation of celiac disease **is not reimbursable**.
13. Serologic testing using an HLA-DQ-gluten tetramer-based assay, including flow cytometry-based HLA-DQ-gluten tetramer assays, **is not reimbursable**.

NOTE 1: Signs and symptoms of celiac disease may include, but are not limited to, the following: unexplained chronic or intermittent diarrhea; unexplained weight loss; unexplained chronic or intermittent abdominal pain or bloating; recurrent nausea or vomiting; unexplained iron deficiency anemia; unexplained vitamin B12 or folate deficiency; unexplained liver transaminase elevations; autoimmune hepatitis; dermatitis herpetiformis; type 1 diabetes; intestinal blockages; unexplained subfertility or miscarriage; unexplained osteoporosis, osteomalacia, or low bone density; and/or primary biliary cirrhosis. Individuals with Down syndrome, Turner syndrome, or Willams-Beuren syndrome are also at high risk for celiac disease. Additionally, in pediatric patients, fatty stools, delayed puberty, amenorrhea, failure to thrive, stunted growth, and/or short stature may also be associated with celiac disease (2-4).

Procedure Codes

The following is not an all-encompassing code list. The inclusion of a code does not guarantee it is a covered service or eligible for reimbursement.

Codes
82784, 83516, 86231, 86255, 86256, 86258, 86364, 88305

References:

1. CDF. What is Celiac disease? Celiac Disease Foundation. <https://celiac.org/celiac-disease/understanding-celiac-disease-2/what-is-celiac-disease/>
2. Husby S, Koletzko S, Korponay-Szabó I, et al. European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020. *J Pediatr Gastroenterol Nutr.* Jan 2020;70(1):141-156. doi:10.1097/mpg.0000000000002497

3. NICE. Coeliac disease overview. <https://pathways.nice.org.uk/pathways/coeliac-disease>
4. NIDDK. Symptoms & Causes of Celiac Disease. U.S. Department of Health and Human Services. Updated October 2020. <https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease/symptoms-causes>
5. Kelly CP. Diagnosis of celiac disease in adults. Updated March 14, 2025. <https://www.uptodate.com/contents/diagnosis-of-celiac-disease-in-adults>
6. Nellikkal SS, Hafed Y, Larson JJ, Murray JA, Absah I. High Prevalence of Celiac Disease Among Screened First-Degree Relatives. *Mayo Clin Proc.* Sep 2019;94(9):1807-1813. doi:10.1016/j.mayocp.2019.03.027
7. Caio G, Volta U, Sapone A, et al. Celiac disease: a comprehensive current review. *BMC Med.* Jul 23 2019;17(1):142. doi:10.1186/s12916-019-1380-z
8. NIDDK. Definition & Facts for Celiac Disease. National Institute of Diabetes and Digestive and Kidney Diseases. Updated October 2020. <https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease/definition-facts>
9. Brown NK, Guandalini S, Semrad C, Kupfer SS. A Clinician's Guide to Celiac Disease HLA Genetics. *Am J Gastroenterol.* Oct 2019;114(10):1587-1592. doi:10.14309/ajg.0000000000000310
10. Tye-Din JA, Galipeau HJ, Agardh D. Celiac Disease: A Review of Current Concepts in Pathogenesis, Prevention, and Novel Therapies. *Frontiers in pediatrics.* 2018;6:350. doi:10.3389/fped.2018.00350
11. Stankovic B, Radlovic N, Lekovic Z, et al. HLA genotyping in pediatric celiac disease patients. *Bosnian journal of basic medical sciences.* Aug 16 2014;14(3):171-6. doi:10.17305/bjbms.2014.3.28
12. Paul SP, Hoghton M, Sandhu B. Limited role of HLA DQ2/8 genotyping in diagnosing coeliac disease. *Scottish medical journal.* Feb 2017;62(1):25-27. doi:10.1177/0036933016689008
13. Sarna VK, Lundin KEA, Morkrid L, Qiao SW, Sollid LM, Christophersen A. HLA-DQ-Gluten Tetramer Blood Test Accurately Identifies Patients With and Without Celiac Disease in Absence of Gluten Consumption. *Gastroenterology.* Mar 2018;154(4):886-896.e6. doi:10.1053/j.gastro.2017.11.006
14. Lau MS, Mooney P, White W, et al. Pre-endoscopy point of care test (Simtomax-IgA/IgG-Deamidated Gliadin Peptide) for coeliac disease in iron deficiency anaemia: diagnostic accuracy and a cost saving economic model. *BMC Gastroenterol.* Sep 15 2016;16:115. doi:10.1186/s12876-016-0521-5
15. FDA. Decision Summary. https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN160026.pdf
16. Olen O, Gudjonsdottir AH, Browaldh L, et al. Antibodies against deamidated gliadin peptides and tissue transglutaminase for diagnosis of pediatric celiac disease. *J Pediatr Gastroenterol Nutr.* Dec 2012;55(6):695-700. doi:10.1097/MPG.0b013e3182645c54
17. Sakly W, Mankai A, Ghdes A, Achour A, Thabet Y, Ghedira I. Performance of anti-deamidated gliadin peptides antibodies in celiac disease diagnosis. *Clinics and research in hepatology and gastroenterology.* Dec 2012;36(6):598-603. doi:10.1016/j.clinre.2012.01.008

18. Bufler P, Heilig G, Ossiander G, Freudenberg F, Grote V, Koletzko S. Diagnostic performance of three serologic tests in childhood celiac disease. *Zeitschrift für Gastroenterologie*. Feb 2015;53(2):108-14. doi:10.1055/s-0034-1385704
19. Silvester JA, Kurada S, Szwajcer A, Kelly CP, Leffler DA, Duerksen DR. Tests for Serum Transglutaminase and Endomysial Antibodies Do Not Detect Most Patients With Celiac Disease and Persistent Villous Atrophy on Gluten-free Diets: a Meta-analysis. *Gastroenterology*. Sep 2017;153(3):689-701.e1. doi:10.1053/j.gastro.2017.05.015
20. Selleski N, Almeida LM, Almeida FC, Pratesi CB, Nobrega YKM, Gandolfi L. PREVALENCE OF CELIAC DISEASE PREDISPOSING GENOTYPES, INCLUDING HLA-DQ2.2 VARIANT, IN BRAZILIAN CHILDREN. *Arquivos de gastroenterologia*. Jan-Mar 2018;55(1):82-85. doi:10.1590/s0004-2803.201800000-16
21. Mubarak A, Spierings E, Wolters V, van Hoogstraten I, Kneepkens CM, Houwen R. Human leukocyte antigen DQ2.2 and celiac disease. *J Pediatr Gastroenterol Nutr*. Apr 2013;56(4):428-30. doi:10.1097/MPG.0b013e31827913f9
22. Vijzelaar R, van der Zwan E, van Gammeren A, et al. Rapid Detection of the Three Celiac Disease Risk Genotypes HLA-DQ2.2, HLA-DQ2.5, and HLA-DQ8 by Multiplex Ligation-Dependent Probe Amplification. *Genetic testing and molecular biomarkers*. Mar 2016;20(3):158-61. doi:10.1089/gtmb.2015.0233
23. Bajor J, Szakács Z, Farkas N, et al. Classical celiac disease is more frequent with a double dose of HLA-DQB1*02: A systematic review with meta-analysis. *PloS one*. 2019;14(2):e0212329. doi:10.1371/journal.pone.0212329
24. Tangermann P, Branchi F, Itzlinger A, et al. Low Sensitivity of Simtomax Point of Care Test in Detection of Celiac Disease in a Prospective Multicenter Study. *Clin Gastroenterol Hepatol*. Aug 2019;17(9):1780-1787.e5. doi:10.1016/j.cgh.2018.09.032
25. Profaizer T, Pole A, Monds C, Delgado JC, Lázár-Molnár E. Clinical utility of next generation sequencing based HLA typing for disease association and pharmacogenetic testing. *Hum Immunol*. Jul 2020;81(7):354-360. doi:10.1016/j.humimm.2020.05.001
26. Gould MJ, Mahmud FH, Clarke ABM, et al. Accuracy of Screening Tests for Celiac Disease in Asymptomatic Patients With Type 1 Diabetes. *Am J Gastroenterol*. Jul 1 2021;116(7):1545-1549. doi:10.14309/ajg.0000000000001193
27. Rubio-Tapia A, Hill ID, Semrad C, et al. American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease. *Am J Gastroenterol*. Jan 1 2023;118(1):59-76. doi:10.14309/ajg.0000000000002075
28. Husby S, Murray JA, Katzka DA. AGA Clinical Practice Update on Diagnosis and Monitoring of Celiac Disease - Changing Utility of Serology and Histologic Measures: Expert Review. *Gastroenterology*. 2019;156(4):885-889. doi:10.1053/j.gastro.2018.12.010
29. Green PHR, Paski S, Ko CW, Rubio-Tapia A. AGA Clinical Practice Update on Management of Refractory Celiac Disease: Expert Review. *Gastroenterology*. Nov 2022;163(5):1461-1469. doi:10.1053/j.gastro.2022.07.086
30. Mearin ML, Agardh D, Antunes H, et al. ESPGHAN Position Paper on Management and Follow-up of Children and Adolescents With Celiac Disease. *J Pediatr Gastroenterol Nutr*. Sep 1 2022;75(3):369-386. doi:10.1097/mpg.0000000000003540

31. Hill ID, Fasano A, Guandalini S, et al. NASPGHAN Clinical Report on the Diagnosis and Treatment of Gluten-related Disorders. *J Pediatr Gastroenterol Nutr.* Jul 2016;63(1):156-65. doi:10.1097/mpg.0000000000001216
32. NICE. Coeliac disease: recognition, assessment and management. National Institute for Health and Care Excellence.
<https://www.nice.org.uk/guidance/ng20/resources/coeliac-disease-recognition-assessment-and-management-pdf-1837325178565>
33. NICE. Coeliac disease. National Institute for Health and Care Excellence.
<https://www.nice.org.uk/guidance/qs134/resources/coeliac-disease-pdf-75545419042501>
34. Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for Celiac Disease: US Preventive Services Task Force Recommendation Statement. *Jama.* Mar 28 2017;317(12):1252-1257. doi:10.1001/jama.2017.1462
35. Bai JC, Ciacci C. World Gastroenterology Organisation Global Guidelines: Celiac Disease February 2017. *Journal of clinical gastroenterology.* Oct 2017;51(9):755-768. doi:10.1097/mcg.0000000000000919
36. Al-Toma A, Volta U, Auricchio R, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. *United European gastroenterology journal.* Jun 2019;7(5):583-613.
doi:10.1177/2050640619844125
37. Ludvigsson JF, Bai JC, Biagi F, et al. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. *Gut.* Aug 2014;63(8):1210-28. doi:10.1136/gutjnl-2013-306578
38. Pelkowski TD, Viera AJ. Celiac disease: diagnosis and management. *Am Fam Physician.* Jan 15 2014;89(2):99-105.
39. AAFP. Screening for Celiac Disease: Recommendation Statement. *Am Fam Physician.* Sep 15 2017;96(6):Online.
40. FDA. Ig_Plex Celiac DGP Panel.
<https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pmn&iid=K140691>
41. FDA. Aptiva Celiac Disease IgA Reagent.
https://www.accessdata.fda.gov/cdrh_docs/reviews/K193604.pdf

Policy Update History:

Approval Date	Effective Date; Summary of Changes
09/26/2025	01/03/2026; Document updated with literature review. The following change was made to Reimbursement Information: added #13 "Serologic testing using an HLA-DQ-gluten tetramer-based assay, including flow cytometry-based HLA-DQ-gluten tetramer assays, is not reimbursable." Removed codes 81376, 81377, 81382, 81383. References revised.
10/30/2024	01/15/2025; Document updated with literature review. Reimbursement Information unchanged. References updated; some added, others revised, some removed.
03/01/2024	03/01/2024: Document updated with literature review. The following changes were made to Reimbursement Information: Added "For individuals who have been diagnosed with celiac disease and who are IgA sufficient, serologic testing with IgA anti-tissue transglutaminase (TTG) may be reimbursable at the following intervals: at the first follow-up visit 3 to 6 months after diagnosis; every 6 months until normalization of anti-TTG levels has occurred; every 12 to 24 months thereafter." "For individuals who have been diagnosed with celiac disease and who are IgA deficient, testing for IgG endomysial antibodies, IgG deamidated gliadin peptide, or IgG TTG may be reimbursable at the following intervals: at the first follow-up visit 3 to 6 months after diagnosis; every 6 months until normalization of IgG levels has occurred; every 12 to 24 months thereafter." "For asymptomatic individuals not at an increased risk for developing celiac disease, testing for celiac disease is not reimbursable." Other revisions made for clarity. References revised.
11/01/2023	11/01/2023: Document updated with literature review. Reimbursement information unchanged. References revised.
11/1/2022	11/01/2022: New policy